<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873431</url>
  </required_header>
  <id_info>
    <org_study_id>IC47-101</org_study_id>
    <nct_id>NCT00873431</nct_id>
  </id_info>
  <brief_title>Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47</brief_title>
  <official_title>An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this clinical study is to investigate the safety and tolerability of
      different dose strengths of IC47 up to 6 months after the first vaccination.

      A total of 32 healthy subjects (male or female) will participate in this clinical study. The
      subjects will be divided into 4 groups of 8 subjects each. Thirty (30) μg or 150 μg of IC47
      will be administered three times in intervals of 42 days each.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1 study will be conducted in four groups of 8 healthy subjects at a single study
      center. 32 subjects will be enrolled. The following table shows the design of the different
      study groups. The amount of protein shown in the table refers to the total protein content
      and is comprised of an equal amount of the three individual components.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of any SAEs (possibly)related to the study vaccine</measure>
    <time_frame>Day 0 - Day 264</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any Grade 3 or higher adverse reactions (possibly)related to the study vaccine</measure>
    <time_frame>Day 0 - Day 264</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited local and systemic AEs within 1 week after vaccination</measure>
    <time_frame>Day 0 - Day 264</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of vaccine‐specific IgG levels</measure>
    <time_frame>Day 0 - Day 264</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>IC47 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg with Alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC47 30 mcg w/o</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg without Alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC47 150 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mcg with Alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC47 150 mcg w/o</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mcg without Alum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC47</intervention_name>
    <description>solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84</description>
    <arm_group_label>IC47 30 mcg</arm_group_label>
    <arm_group_label>IC47 30 mcg w/o</arm_group_label>
    <arm_group_label>IC47 150 mcg</arm_group_label>
    <arm_group_label>IC47 150 mcg w/o</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Healthy adults ≥ 18 to &lt;/= 65

          -  female subjects: post‐menopausal or practicing reliable methods of contraception
             during the study

        Exclusion Criteria:

          -  History of autoimmune diseases and malignancies.

          -  History of severe hypersensitivity reactions and anaphylaxis.

          -  Immunodeficiency due to immunosuppressive therapy.

          -  Infection with HIV, Hepatitis B or Hepatitis C.

          -  Pregnancy, lactation

          -  Vulnerable subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyn Hatzenbichler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH, Institute for Clinical Pharmacology</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of pneumococcal infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

